MX2024009147A - Composiciones de acidos grasos liberadoras de linfa y usos de las mismas para la incorporacion linfatica y tratamiento de enfermedades sistemicas. - Google Patents

Composiciones de acidos grasos liberadoras de linfa y usos de las mismas para la incorporacion linfatica y tratamiento de enfermedades sistemicas.

Info

Publication number
MX2024009147A
MX2024009147A MX2024009147A MX2024009147A MX2024009147A MX 2024009147 A MX2024009147 A MX 2024009147A MX 2024009147 A MX2024009147 A MX 2024009147A MX 2024009147 A MX2024009147 A MX 2024009147A MX 2024009147 A MX2024009147 A MX 2024009147A
Authority
MX
Mexico
Prior art keywords
lymph
fatty acids
lymphatic
incorporation
diseases
Prior art date
Application number
MX2024009147A
Other languages
English (en)
Spanish (es)
Inventor
Richard Preston Mason
Richard Louis Dunbar
Original Assignee
Amarin Pharmaceuticals Ie Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amarin Pharmaceuticals Ie Ltd filed Critical Amarin Pharmaceuticals Ie Ltd
Publication of MX2024009147A publication Critical patent/MX2024009147A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J7/00—Phosphatide compositions for foodstuffs, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024009147A 2022-01-26 2023-01-26 Composiciones de acidos grasos liberadoras de linfa y usos de las mismas para la incorporacion linfatica y tratamiento de enfermedades sistemicas. MX2024009147A (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202263303365P 2022-01-26 2022-01-26
US202263303383P 2022-01-26 2022-01-26
US202263304042P 2022-01-28 2022-01-28
US202263334071P 2022-04-22 2022-04-22
US202263334065P 2022-04-22 2022-04-22
US202263340292P 2022-05-10 2022-05-10
US202263340304P 2022-05-10 2022-05-10
US202263342509P 2022-05-16 2022-05-16
US202263348908P 2022-06-03 2022-06-03
PCT/US2023/011651 WO2023146984A1 (en) 2022-01-26 2023-01-26 Lymph-releasing compositions of fatty acids and uses thereof for lymphatic incorporation and systemic disease treatment

Publications (1)

Publication Number Publication Date
MX2024009147A true MX2024009147A (es) 2024-08-06

Family

ID=87472560

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024009147A MX2024009147A (es) 2022-01-26 2023-01-26 Composiciones de acidos grasos liberadoras de linfa y usos de las mismas para la incorporacion linfatica y tratamiento de enfermedades sistemicas.

Country Status (10)

Country Link
US (1) US20240165066A1 (enExample)
EP (1) EP4468884A4 (enExample)
JP (1) JP2025503961A (enExample)
KR (1) KR20240142470A (enExample)
AU (1) AU2023213684A1 (enExample)
CA (1) CA3248854A1 (enExample)
IL (1) IL314467A (enExample)
MA (1) MA66915A1 (enExample)
MX (1) MX2024009147A (enExample)
WO (1) WO2023146984A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX377553B (es) * 2009-04-29 2025-03-10 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
WO2020245816A1 (en) 2019-06-03 2020-12-10 Migal Galilee Research Institute Ltd. 5,6-dihete lactone for treatment of microvascular dysfunction
GB202400712D0 (en) * 2024-01-18 2024-03-06 Northwood Consultants Ltd Anti-inflammatory composition and use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3069322A (en) * 1958-05-28 1962-12-18 Bergstrom Sune Pge and pgf
SE8604117D0 (sv) * 1986-09-29 1986-09-29 Kabivitrum Ab Composition
US5262168A (en) * 1987-05-22 1993-11-16 The Liposome Company, Inc. Prostaglandin-lipid formulations
US5262437A (en) * 1990-12-10 1993-11-16 Allergan, Inc. Homo-prostaglandin derivatives as ocular hypotensives
US6077525A (en) * 1998-04-10 2000-06-20 The George Washington University Use of conjugated linoleic acids
US20060165735A1 (en) * 2002-06-18 2006-07-27 Abril Jesus R Stable emulsions of oils in aqueous solutions and methods for producing same
TWI365716B (en) * 2003-12-02 2012-06-11 Suntory Holdings Ltd Oil or fat and oil compositions containing phospholipids and a long-chain polyunsaturated fatty acid supply compound, and food using same
US7893106B2 (en) * 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
US20070042008A1 (en) * 2005-08-18 2007-02-22 Bodybio, Inc. Compositions containing phosphatidylcholine and essential fatty acids
EP1983977A4 (en) * 2006-01-31 2011-11-30 Martek Biosciences Corp OXYLIPINES FROM STEARIDONIC ACID AND GAMMA-LINOLIC ACID AND METHOD FOR THE PRODUCTION AND USE THEREOF
RU2470644C2 (ru) * 2006-09-05 2012-12-27 Кью.Пи. КОПЭРЕЙШН Стабильная жировая эмульсия (варианты), способ ее получения, эмульгирующий агент и способы стабилизации простагландина и капель жира
WO2011060084A1 (en) * 2009-11-10 2011-05-19 MyCell Holdings Limited Stabilized formulations of fatty acids
EP2664329A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
CA2894709C (en) * 2012-12-24 2022-08-09 Qualitas Health, Ltd. Eicosapentaenoic acid (epa) formulations
CA2974495C (en) * 2015-01-21 2023-05-23 Mochida Pharmaceutical Co., Ltd. .omega.-3 fatty acid self-emulsifying composition
KR102488648B1 (ko) * 2015-01-21 2023-01-12 모치다 세이야쿠 가부시키가이샤 ω3 지방산의 자기 유화 조성물
JP6783891B2 (ja) * 2019-04-10 2020-11-11 持田製薬株式会社 ω3脂肪酸の自己乳化組成物

Also Published As

Publication number Publication date
JP2025503961A (ja) 2025-02-06
EP4468884A4 (en) 2025-12-10
MA66915A1 (fr) 2025-10-31
KR20240142470A (ko) 2024-09-30
AU2023213684A1 (en) 2024-08-15
US20240165066A1 (en) 2024-05-23
WO2023146984A1 (en) 2023-08-03
EP4468884A1 (en) 2024-12-04
CA3248854A1 (en) 2023-08-03
IL314467A (en) 2024-09-01

Similar Documents

Publication Publication Date Title
US5589508A (en) Use of an emulsion to prepare an intravensously administered medicament for treating skin diseases
JP2796838B2 (ja) 精神分裂症および/または関連した晩発性運動障害の治療のための薬剤を製造する方法
JP4828074B2 (ja) ポリエニルホスファチジルコリンを使用する皮膚の損傷の治療
WO2009091538A8 (en) Pharmaceutical composition comprising epa and dha for treating hypertriglyceridemia and hypercholesterolemia
RU2019137026A (ru) Сложные эфиры для лечения офтальмологических воспалительных заболеваний
CZ20033196A3 (cs) Prostředky obsahující koenzym Q a EPA nebo jinou esenciální mastnou kyselinu
AU2003238240A1 (en) ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE
BRPI1015120B8 (pt) Composto lipídico alfa-substituídos, derivados de ácidos graxos beta-oxo poli-insaturados, composição farmacêutica e lipídica e métodos para produzir composto lipídico e ácido 2-((5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaeniloxi)butanóico
KR20000049016A (ko) 에이코사펜타엔산 및/또는 스테아리돈산을 포함하여 이루어지는약제학적 제제
JP2004536059A (ja) 微生物、遺伝的に改変された植物種子および海洋生物由来のω−3および/またはω−6高度不飽和脂肪酸を含有する極性脂質の豊富な画分の生成および使用
ES2255467T1 (es) Acidos grasos de cadena media, gliceridos y analogos como estimuladores de la eritropoyesis.
MA66915A1 (fr) Compositions d'acides gras à libération de lymphe et leurs utilisations pour l'incorporation lymphatique et le traitement de maladies systémiques
JP2003517043A (ja) 共役脂肪酸およびその関連化合物、並びにその酵素による製造法
CA1287297C (en) Iron - containing compositions and method for treatment of cancer
JPH0832628B2 (ja) トリグリセリド組成物
WO2006111633A3 (fr) Utilisation de la lecithine comme medicament dans le traitement du psoriasis
WO2011137160A3 (en) Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (ldl) per-oxidation in humans
CN1135218C (zh) 脂类混合物及其用途
GEP20146088B (en) Pharmaceutical composition including docosahexaenoic acid (dha) ester to be parenterally administered
RU2008108078A (ru) Новые препаративные формы, включающие фенофибрат и статин, и соответствующие способы лечения
JP2007500732A (ja) Mlv化粧品
JP7819412B2 (ja) セトレイン酸組成物
US20010033847A1 (en) Dermatologic preparation
EP1909800B1 (de) Acylglycerophospholipide zur behandlung von krebs-begleiterscheinungen
Patel et al. High dose ω3 eicosapentaenoic acid and docosahexaenoic acid block, whereas ω6 arachidonic acid accelerates, MYCN-driven tumorigenesis in vivo